Novel Marker of Early ES Cell Differentiation
A novel cell surface marker that is able to determine both the pluripotency and early differentiation state of an ES cell population in a single, rapid, non-destructive assay. This marker is a valuable tool for a wide range of ES cell techniques. Well characterised monoclonal antibodies to mouse and human antigens are available.
Contact: Dr Tanya Moore, tmoore@CancerTechnology.com
 Further details can be accessed here
Transposon Mediated Genomic DNA Integration
Non-exclusive rights are available to a technology enabling the integration of DNA into host genomes across a variety of species, using transposons from the Tc1/Mariner family derived from Drosophila and C. elegans. Applications include gene therapy including stem cell research, gene tagging and genotype/phenotype analysis.
Contact: Dr Ruth Nebuer, rnebauer@CancerTechnology.com
CyMap: A Novel Imaging Device with Multiple Applications
CyMap’ is a novel CCD-based lens-free imaging system with potential applications in automating a wide-range of live cell-based assays, diagnostic assays or industrial processes. The simple system utilises only low-cost components, is robust and readily miniaturised. Potential applications included tissue culture cell imaging systems, blood cell counting, male fertility testing, pathogen/parasite detection and bioreactor QC. The system has been extensively validated for automating cellular assays including cell division, migration, colony formation and wound healing, as well as for integration with microfluidic platforms. A patent application covering the CyMap technology has been filed and exclusive multi-territory licenses are available to further develop and commercialise the technology in multiple fields. The technology was recently awarded first prize in the Medical and Healthcare category, as well as the overall Grand Prix prize of the prestigious The Engineer’s Technology and Innovation Awards, which recognise and honour innovation in the UK.
Contact: Dr Laura Fletcher, lfletcher@CancerTechnology.com
Further details can be accessed here
Iduronate Scalable Chemistry Methods
A novel, scalable synthetic route has been developed and optimised for the production of synthetic polysaccharides containing the L-iduronate subunit e.g. heparin-type polysaccharides. Reactions at ambient temperature using inexpensive reagents and the key stereochemical step involving purification by crystallization enables large-scale synthesis, facilitating access to larger amounts of various L-iduronate targets. Scalability underpins the potential for viable development of L-ido-containing heparan-related saccharides for clinical evaluations. The patent portfolio is available for licensing in the fields of research tools and therapeutic development outside of CRT’s Oligosaccharides as Inhibitors of Angiogenesis programme.
Contact: Dr Martyn Bottomley, mbottomley@CancerTechnology.com
Transgenic Mice and Cell Lines
CRT has a portfolio of transgenic mice encompassing conditional knock-ins and knock-outs and animal models, derived from these sources. Noteworthy examples include two independent psoriasis models, BRCA1 and BRCA2 breast cancer models and a metastatic breast cancer model. A portfolio of these cell lines is also available for licensing, including TR146, a cell line that represents a unique in vitro model of human buccal mucosa. You can browse our Mouse and Cell Line portfolio from here.
Contact: Reagents@CancerTechnology.com
Cytochrome b5 KO Mouse Model for Study of Drug Metabolism
A mouse model has been developed, in which cytochrome b5 has been knockout in the liver. The loss of cytochrome b5 results in significant reduction of drug metabolism. This model is a valuable tool for the studying of cytochrome b5 in metabolism and the evaluation of drug efficacy, bioavailability and toxicity in vivo. Liver cells extracted from the mice (hepatic microsomes) could also be isolated and used to test new drugs in vitro.
Contact: Dr Fatima Kranc, fkranc@CancerTechnology.com
Further details can be accessed here
Cytochrome b5 KO Mouse Model for Study of Steatosis
A mouse model has been developed, in which cytochrome b5 has been knockout in the liver. The loss of cytochrome b5 results in significant reduction of the P450 metabolism and the development of hepatic vesicular steatosis. The model phenocopies the genesis and progression of non-alcoholic steatosis. This model is a valuable tool for the studying of the role of cytochrome b5 in steatosis and the evaluation of new prophylactics or therapeutics for steatosis.
Contact: Dr Fatima Kranc, fkranc@CancerTechnology.com
Further details can be accessed here
Endothelial Tissue-specific and Inducible Cre Transgenic Mice
Inducible Cre transgenic strains expressing the Cre-ER(T2) gene switch under the control of VECAD or BMX promoters. These mice can be crossed with mice carrying LoxP-flanked genes of interest to generate temporally controlled tissue-specific deletions upon tamoxifen treatment. Tamoxifen treatment of the VECAD-Cre-ER(T2) embryos induces Cre activity in >90% of endothelial cells of all arteries, veins and in the lymphatic system. Tamoxifen treatment of adult mice induces Cre activity only in smaller vascular beds. These mice may be used for study of genes involved in vascular development and pathological angiogenesis in adult mice. Tamoxifen treatment of the BMX-Cre-ER(T2) mice induces Cre activity in arterial but not venous endothelial cells. These mice may be useful for study of genes involved in pathological arterial conditions, including artherosclerosis.
Contact: Dr Raj Mehta, rmehta@CancerTechnology.com
Further details can be accessed here
Antibody Portfolio
CRT's antibody portfolio currently consists of over 450 antibodies. Hybridomas are available for licensing in the fileds of research and in vitro diagnostics, and purified antibody is supplied for research purposes on a sales basis. Copies of the antibody portfolio are available both on request and online in a searchable format, providing a full technical profile for each antibody. Click here for the online version.
Contact: Reagents@CancerTechnology.com
|
